BioLineRx vs XTL Biopharmaceuticals
BLRX and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLRX and XTLB compare
BioLineRx scores higher on the StockData Score (3 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLRX | XTLB |
|---|---|---|
| Size and price | ||
| Share price | $1.12 | $1.62 |
| Change, 1 year | −65.3% | −56.0% |
| Change, 5 years | −98.9% | −86.5% |
| Beta (5Y) | 1.56 | 1.14 |
| Employees | 20 | 3 |
| StockData Score | ||
| Total score | 3 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −95.9% | – |
| Profitability | ||
| Gross margin | 80.5% | – |
| Operating margin | −872% | – |
| FCF margin | −686% | – |
| Return on invested capital | −59.7% | – |
| Financial health | ||
| Debt / equity | 0.33 | – |
| Interest coverage | −8.0× | −6.3× (better) |
| Current ratio | 1.20 | – |
| Ownership | ||
| Held by institutions | 0.00% | 0.00% |
| Held by insiders | 0.39% | 0.00% |
Go deeper
- BLRX stock overview
- BLRX income statement
- BLRX valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.